No Data
No Data
Are Robust Financials Driving The Recent Rally In Grand Pharmaceutical Group Limited's (HKG:512) Stock?
Ping An Securities: Nuclear medicine has multiple clinical advantages, and high barriers to entry have created an oligopolistic monopoly pattern.
It is expected that from 2023 to 2030, China's nuclear medicine market will grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6%.
CICC: First to give Grandpharma a 'Outperform' rating, with a target price of HK$5.4.
CICC predicts that grandpharma's EPS will be HKD 0.57 and HKD 0.60 respectively in 2024 and 2025.
Grand Pharmaceutical Group Acquires Three Pharmaceutical Firms
Grand Pharma Expands With Key Acquisitions
Grandpharma (00512.HK): Completed the acquisition of Tianjin Tianbian and BeiGene Pharmaceuticals.
On July 17th, Gelonghui reported that Grandpharma (00512.HK) announced that the group has recently completed the change registration of the 100% equity of Tianjin Tianbian Pharmaceutical Co., Ltd. and Nanchang Bei Ji Pharmaceutical Co., Ltd. and Jiangxi Bai'an Baiyu Pharmaceutical Technology Co., Ltd. (the latter two are collectively referred to as "Bei Ji Pharmaceutical"). These two acquisitions will further deepen the group's industrial layout in the cardiovascular and cerebrovascular emergency sector and the respiratory and critical care sector.
No Data